查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1982434

全球疫苗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 201 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计疫苗市场将从 2025 年的 1,533 亿美元成长到 2034 年的 2,295.9 亿美元，2026 年至 2034 年的复合年增长率为 4.59%。

由于人们对疾病预防和公共卫生的日益关注，全球疫苗市场正经历显着增长。疫苗在保护人们感染疾病发挥着至关重要的作用，它能刺激免疫系统识别并对抗有害病原体。世界各国政府和卫生机构正在扩大免疫接种计划，以改善公共卫生状况。

多种因素正在推动疫苗市场成长。主要因素包括公众健康意识的提高和政府对疫苗接种计画的投入增加。此外，生物技术和疫苗研发技术的进步也使得更有效的新型疫苗得以研发。全球疫苗宣传活动显着提升了对免疫产品的需求。

随着研究机构不断研发针对新兴感染疾病的疫苗，疫苗市场预计将持续成长。 mRNA和先进递送系统等技术创新正在提高疫苗的效力和生产效率。在全球医疗卫生基础设施持续投入的背景下，疫苗对于疾病预防和公共卫生保护仍将至关重要。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球疫苗市场：依疫苗类型划分

  • 市场分析、洞察与预测
  • 失活
  • 减毒活病毒疫苗
  • 类毒素
  • 组合型
  • 其他的

第五章：全球疫苗市场：以价态划分

  • 市场分析、洞察与预测
  • 疫苗单价
  • 多价疫苗

第六章 全球疫苗市场：依给药途径划分

  • 市场分析、洞察与预测
  • 口服
  • 注射药物
  • 其他的

第七章：全球疫苗市场：依适应症划分

  • 市场分析、洞察与预测
  • 流感
  • 肝炎
  • 脊髓灰质炎
  • 病菌感染
  • 肺炎链球菌感染
  • DTP
  • 轮状病毒
  • MMR
  • 人类乳突病毒
  • 其他的

第八章 全球疫苗市场：依通路划分

  • 市场分析、洞察与预测
  • 向机构销售
  • 医院药房
  • 零售药房

第九章 全球疫苗市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十一章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • AstraZeneca
    • GlaxoSmithKline Plc
    • Sanofi Pasteur SA
    • Pfizer Inc
    • Panacea Biotec
    • Merck & Co. Inc
    • Janssen Pharmaceutical Companies
    • Serum Institute Of India Pvt. Ltd
    • Emergent BioSolutions Inc
    • CSL Limited
    • Bavarian Nordic
    • IBSS Biomed SA
    • Novavax AB
    • Mitsubishi Tanabe Pharma Corporation
简介目录
Product Code: VMR11211825

The Vaccine Market size is expected to reach USD 229.59 Billion in 2034 from USD 153.30 Billion (2025) growing at a CAGR of 4.59% during 2026-2034.

The global vaccine market has experienced substantial growth due to increasing focus on disease prevention and public health initiatives. Vaccines play a critical role in protecting populations from infectious diseases by stimulating the immune system to recognize and combat harmful pathogens. Governments and healthcare organizations worldwide have expanded immunization programs to improve public health outcomes.

Several factors are driving the growth of the vaccine market. Rising awareness about preventive healthcare and increasing government funding for vaccination programs are major contributors. Advances in biotechnology and vaccine development technologies have also enabled the creation of new and more effective vaccines. Global vaccination campaigns have significantly increased demand for immunization products.

Looking ahead, the vaccine market is expected to continue growing as research institutions develop vaccines for emerging diseases. Technological innovations such as mRNA and advanced delivery systems are improving vaccine effectiveness and production efficiency. With ongoing investments in global healthcare infrastructure, vaccines will remain essential for disease prevention and public health protection.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

  • Inactivated
  • Live Attenuated
  • Toxoid
  • Conjugate
  • Others

By Valence

  • Monovalent
  • Multivalent

By Route of Administration

  • Oral
  • Injectable
  • Others

By Indication

  • Influenza
  • Hepatitis
  • Polio
  • Meningococcal Disease
  • Pneumococcal Disease
  • DTP
  • Rotavirus
  • MMR
  • Human Papilloma Virus
  • Others

By Distribution Channel

  • Institutional Sales
  • Hospital Pharmacies
  • Retail Pharmacies

COMPANIES PROFILED

  • AstraZeneca, GlaxoSmithKline plc, Sanofi Pasteur SA, Pfizer Inc, Panacea Biotec, Merck Co Inc, Janssen Pharmaceutical Companies, Serum Institute of India Pvt Ltd, Emergent BioSolutions Inc, CSL Limited, Bavarian Nordic, IBSS Biomed SA, Novavax AB, Mitsubishi Tanabe Pharma Corporation
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL VACCINE MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Vaccine Type
  • 4.2. Inactivated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Live Attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Toxoid Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.5. Conjugate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL VACCINE MARKET: BY VALENCE 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Valence
  • 5.2. Monovalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Multivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL VACCINE MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL VACCINE MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

  • 7.1. Market Analysis, Insights and Forecast Indication
  • 7.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.4. Polio Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.5. Meningococcal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.6. Pneumococcal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.7. DTP Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.8. Rotavirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.9. MMR Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.10. Human Papilloma Virus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.11. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Institutional Sales Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.2.1 By Vaccine Type
    • 9.2.2 By Valence
    • 9.2.3 By Route Of Administration
    • 9.2.4 By Indication
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.3.1 By Vaccine Type
    • 9.3.2 By Valence
    • 9.3.3 By Route Of Administration
    • 9.3.4 By Indication
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.4.1 By Vaccine Type
    • 9.4.2 By Valence
    • 9.4.3 By Route Of Administration
    • 9.4.4 By Indication
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.5.1 By Vaccine Type
    • 9.5.2 By Valence
    • 9.5.3 By Route Of Administration
    • 9.5.4 By Indication
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.6.1 By Vaccine Type
    • 9.6.2 By Valence
    • 9.6.3 By Route Of Administration
    • 9.6.4 By Indication
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL VACCINE INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 AstraZeneca
    • 11.2.2 GlaxoSmithKline Plc
    • 11.2.3 Sanofi Pasteur SA
    • 11.2.4 Pfizer Inc
    • 11.2.5 Panacea Biotec
    • 11.2.6 Merck & Co. Inc
    • 11.2.7 Janssen Pharmaceutical Companies
    • 11.2.8 Serum Institute Of India Pvt. Ltd
    • 11.2.9 Emergent BioSolutions Inc
    • 11.2.10 CSL Limited
    • 11.2.11 Bavarian Nordic
    • 11.2.12 IBSS Biomed S.A
    • 11.2.13 Novavax AB
    • 11.2.14 Mitsubishi Tanabe Pharma Corporation